GRACEcast Cancer 101 Video
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)
- Autor: Podcast
- Narrador: Podcast
- Editor: Podcast
- Mas informaciones
Informações:
Sinopsis
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
